Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (Weighted Average) (2021 - 2025)

Prime Medicine (PRME) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $148.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 25.43% year-over-year to $148.8 million, compared with a TTM value of $148.8 million through Dec 2025, up 25.43%, and an annual FY2025 reading of $148.8 million, up 25.43% over the prior year.
  • Shares Outstanding (Weighted Average) was $148.8 million for Q4 2025 at Prime Medicine, up from $139.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $148.8 million in Q4 2025 and bottomed at $11.8 million in Q3 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $82.0 million, with a median of $90.7 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) skyrocketed 367.52% in 2023, then rose 14.85% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $13.0 million in 2021, then soared by 161.23% to $33.9 million in 2022, then surged by 168.42% to $91.0 million in 2023, then skyrocketed by 30.37% to $118.6 million in 2024, then rose by 25.43% to $148.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PRME at $148.8 million in Q4 2025, $139.2 million in Q3 2025, and $128.4 million in Q2 2025.